Spots Global Cancer Trial Database for small cell lung cancer (sclc)
Every month we try and update this database with for small cell lung cancer (sclc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | NCT02934503 | Small Cell Lung... | Pembrolizumab Cisplatin Carboplatin Etoposide Radiation thera... | 19 Years - | NYU Langone Health | |
| Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC | NCT05158491 | Small Cell Lung... | JK-1201I | 18 Years - 70 Years | JenKem Technology Co., Ltd. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma | NCT01703481 | Tumor or Lympho... | JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... | 18 Years - | Janssen Research & Development, LLC | |
| Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | NCT05027100 | Small Cell Lung... | Anlotinib Tisle... | 18 Years - 75 Years | Guangzhou University of Traditional Chinese Medicine | |
| Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC) | NCT03425825 | Lung Cancer | 18 Years - | Bristol-Myers Squibb | ||
| Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy | NCT05815160 | Small Cell Lung... | Debio 0123 Etoposide Carboplatin | 18 Years - | Debiopharm International SA | |
| Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting | NCT05826756 | Lung Cancer Pat... Caregivers | There are no in... | 18 Years - | LUNGevity Foundation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. | NCT04285866 | Small Cell Lung... | Durvalumab | 18 Years - | Fundación GECP | |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer | NCT05740566 | Small Cell Lung... | Tarlatamab Lurbinectedin Topotecan Amrubicin | 18 Years - | Amgen | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor | NCT05194982 | Locally Advance... | BL-B01D1 | 18 Years - 75 Years | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | NCT02769832 | Small Cell Lung... | Nab-paclitaxel Gemcitabine | 18 Years - 99 Years | University of Iowa | |
| A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | NCT03361228 | Solid Tumors | INCB001158 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | NCT02030184 | Small Cell Lung... Neuroendocrine ... Large Cell Neur... | Rhenium Re 188-... | 18 Years - | University of Maryland, Baltimore | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma | NCT01703481 | Tumor or Lympho... | JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... | 18 Years - | Janssen Research & Development, LLC | |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | NCT02712905 | Solid Tumors an... | INCB059872 all-trans retin... azacitidine nivolumab | 18 Years - | Incyte Corporation | |
| Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) | NCT01210131 | Small Cell Lung... | [18F]HX4 | 18 Years - | Maastricht Radiation Oncology | |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | NCT02069158 | Breast Cancer NSCLC Ovary Cancer Endometrial Can... Small Cell Lung... Head and Neck (... | PF-05212384 Paclitaxel Carboplatin | 18 Years - | Oncology Institute of Southern Switzerland | |
| Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) | NCT03061812 | Small Cell Lung... | Rovalpituzumab ... Topotecan Dexamethasone | 18 Years - | AbbVie | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | NCT03033511 | Small Cell Lung... | Placebo for dex... Placebo for rov... Rovalpituzumab ... Dexamethasone | 18 Years - | AbbVie | |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | NCT02069158 | Breast Cancer NSCLC Ovary Cancer Endometrial Can... Small Cell Lung... Head and Neck (... | PF-05212384 Paclitaxel Carboplatin | 18 Years - | Oncology Institute of Southern Switzerland | |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | NCT03708328 | Solid Tumors Metastatic Mela... Non-small Cell ... Small Cell Lung... Esophageal Squa... | Lomvastomig | 18 Years - | Hoffmann-La Roche | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | NCT03811652 | Non Small Cell ... Head and Neck S... Small Cell Lung... Pancreatic Duct... Colorectal Canc... Metastatic Cast... | MEDI7247 | 18 Years - 101 Years | MedImmune LLC | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia: | NCT04836975 | Lung Cancer | - | AstraZeneca | ||
| A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | NCT03066778 | Small Cell Lung... | Pembrolizumab Normal saline s... Carboplatin Cisplatin Etoposide | 18 Years - | Merck Sharp & Dohme LLC | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) | NCT03033511 | Small Cell Lung... | Placebo for dex... Placebo for rov... Rovalpituzumab ... Dexamethasone | 18 Years - | AbbVie | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | NCT01719861 | Small Cell Lung... Neuroendocrine ... | Desipramine HCL | 18 Years - | Stanford University | |
| A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors | NCT03071757 | Advanced Solid ... | ABBV-368 ABBV-181 | 18 Years - | AbbVie | |
| Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | NCT02934503 | Small Cell Lung... | Pembrolizumab Cisplatin Carboplatin Etoposide Radiation thera... | 19 Years - | NYU Langone Health | |
| AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | NCT02511795 | Refractory Soli... Relapsed Small ... | AZD1775 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | NCT00527735 | Lung Cancer Small Cell Lung... Carcinoma, Non-... | Ipilimumab Placebo Paclitaxel Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | NCT02628067 | Advanced Cancer Anal Carcinoma Anal Cancer Biliary Cancer Cholangiocarcin... Bile Duct Cance... Neuroendocrine ... Carcinoid Tumor Endometrial Car... Endometrial Can... Cervical Carcin... Cervical Cancer Vulvar Carcinom... Vulvar Cancer Small Cell Lung... Small Cell Lung... Mesothelioma Thyroid Carcino... Thyroid Cancer Salivary Gland ... Salivary Gland ... Salivary Cancer Parotid Gland C... Advanced Solid ... Colorectal Carc... | pembrolizumab pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC) | NCT03425825 | Lung Cancer | 18 Years - | Bristol-Myers Squibb | ||
| Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | NCT04727853 | Small Cell Lung... | irinotecan lipo... | 18 Years - | CSPC Ouyi Pharmaceutical Co., Ltd. | |
| Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | NCT00527735 | Lung Cancer Small Cell Lung... Carcinoma, Non-... | Ipilimumab Placebo Paclitaxel Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network | NCT01574300 | Non-small Cell ... Small Cell Lung... | therapeutic int... | 18 Years - | Addario Lung Cancer Medical Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
